Skip to content
Open access

Onabotulinum Toxin A (BoNTA) in the Treatment of Chronic and High-Frequency Episodic Migraine: A Real-World Study

Oct 2026 · Pharmaceuticals · Vol 19 · 0 citations · 53 references
Medicine

TL;DR

In this retrospective uncontrolled cohort, reductions in headache frequency and other clinical improvements were observed during BoNTA treatment in patients with CM and HFEM, and these findings cannot establish the efficacy of BoNTA in HFEM.

Abstract

Background/Objectives. Although onabotulinumtoxinA (BoNTA) is an established therapy for chronic migraine (CM), its effectiveness in high-frequency episodic migraine (HFEM) remains uncertain. We conducted an 18-year, single-center, retrospective study of patients treated with BoNTA for CM or HFEM. Methods. We included 136 patients with CM and 71 with HFEM who had previously received multiple oral preventive therapies, who received BoNTA using an injection paradigm based on the PREEMPT protocol. Clinical and laboratory data were collected. Results. Responder rates, defined as a ≥50% reduction in monthly headache days, were 65.4% in CM and 71.8% in HFEM. Both groups showed a significant reduction in the frequency of headache days and headache intensity and improved response to symptomatic treatment. The mean duration of benefit among responders was 3.66 (SD 2.12) months in CM and 3.78 (SD 1.11) months in HFEM. No statistically significant associations were detected between responder status and either the duration of previous preventive treatment or the neutrophil-to-lymphocyte ratio. Responders with CM showed a non-significant tendency to have used a lower number of preventive treatments compared with partial responders plus non-responders. At the end of follow-up, 42.6% of CM and 57.8% of HFEM patients remained on BoNTA. Conclusions. In this retrospective uncontrolled cohort, reductions in headache frequency and other clinical improvements were observed during BoNTA treatment in patients with CM and HFEM. Because this study lacked a control group, these findings cannot establish the efficacy of BoNTA in HFEM and should be interpreted as exploratory.

Read PDF

Similar papers

2026

COMPARATIVE EFFICACY OF 200 UNITS VERSUS 155 UNITS OF ONABOTULINUMTOXIN A FOR CHRONIC MIGRAINE.

The study concludes that administering 200 U of OnaBT-A, significantly decreases the frequency and duration of headaches when compared to 155 U, and recommends considering this dosage for patients who do not accomplish adequate relief with 155 U of OnaBT-A.

W. Alkhaffaf, M. Alkataan · 0 citations
Open access Oct 2026

Triple Preventive Therapy with OnabotulinumtoxinA, Fremanezumab, and Atogepant in Treatment-Resistant Chronic Migraine: A 52-Week Pilot Case Series (TRIPLE Cohort).

INTRODUCTION A substantial proportion of patients with chronic migraine (CM) experience persistent disability despite advanced preventive monotherapies, including onabotulinumtoxinA (BoNT-A) and calcitonin gene-related peptide (CGRP)-targeted drugs. Evidence supporting combination strategies remains limited. We evaluat...

M. Romozzi, L. Iannone, A. Russo et al. · 0 citations
Open access Sep 2026

Real-World Effectiveness and Safety of Anti-CGRP Monoclonal Antibodies in the Prevention of High-Frequency Episodic and Chronic Migraine in Romania—A Multicenter Retrospective Observational Study

In this Romanian real-world cohort, anti-CGRP monoclonal antibody treatment was associated with substantial reductions in migraine/headache frequency in patients with HFEM and CM, and generally well-tolerated.

Alin Ciubotaru, Albert Vamanu, Cristina Grosu et al. · 0 citations
Open access Nov 2026

Atogepant for preventive treatment of episodic cluster headache: A single-center case series of 18 patients.

BackgroundCluster headache (CH) is a highly disabling primary headache disorder characterized by severe unilateral attacks occurring in bouts. Calcitonin gene-related peptide plays a key role in CH pathophysiology, yet preventive treatment options remain limited. We aimed to evaluate the short-term clinical effects of...

Yoo-ha Hong, Mi-Kyoung Kang, Soo-Jin Cho · 0 citations
Open access Sep 2026

Comparative effectiveness and safety of topiramate versus amitriptyline for the prophylactic management of chronic migraine: a prospective comparative study

Background Chronic migraine is a chronic disabling neurological disease and has a significant impact on quality of life. Topiramate and amitriptyline are commonly used for migraine prevention, but treatment decisions should consider their effectiveness and safety profiles. This study aimed to compare the effectiveness...

M. Karami, Amber Hassan, Amal M. Alkhotani et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.